Guideline for management of postmeal glucose

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 18, Issue 4, 2008, Pages

  Ceriello, Antonio ^a   Colagiuri, Stephen ^b   Gerich, John ^c   Tuomilehto, Jaakko ^d  

^a WALSGRAVE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF ROCHESTER   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Blood glucose control; Complications; Diabetes; Postmeal glucose; Recommendations; Treatment

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

BLOOD; DIABETES MELLITUS; DIET THERAPY; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRACTICE GUIDELINE; REVIEW; RISK FACTOR;

BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; POSTPRANDIAL PERIOD; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 44149119287     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2008.01.012     Document Type: Review

References (146)

1. Diabetes Atlas. third ed. (2006), International Diabetes Federation
2. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 14 (1993) 977-986
3. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28 2 (1995) 103-117
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 9131 (1998) 837-853
5. Huxley R., Barzi F., and Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332 7533 (2006) 73-78
6. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 4 (1998) 229-234
7. Niskanen L., Turpeinen A., Penttila I., and Uusitupa M.I. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care 21 11 (1998) 1861-1869
8. Lustman P.J., and Clouse R.E. Depression in diabetic patients: the relationship between mood and glycemic control. J Diabetes Complicat 19 2 (2005) 113-122
9. Anderson R.J., Freedland K.E., Clouse R.E., and Lustman P.J. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 24 6 (2001) 1069-1078
10. Diabetes Control and Complications Trial (DCCT) Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44 8 (1995) 968-983
11. Hanefeld M., Chiasson J.L., Koehler C., Henkel E., Schaper F., and Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 35 5 (2004) 1073-1078
12. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 25 (2005) 2643-2653
13. Stettler C., Allemann S., Juni P., Cull C.A., Holman R.R., Egger M., et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 152 1 (2006) 27-38
14. Diabetes Control and Complications Trial (DCCT) Research Group. The absence of a glycemic threshold for the development of longterm complications: the perspective of the diabetes control and complications trial. Diabetes 45 10 (1996) 1289-1298
15. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 7258 (2000) 405-412
16. Khaw K.T., Wareham N., Luben R., Bingham S., Oakes S., Welch A., et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 322 7277 (2001) 15-18
17. DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161 3 (2001) 397-405
18. Nakagami T., Qiao Q., Tuomilehto J., Balkau B., Tajima N., Hu G., et al. Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. Eur J Cardiovasc Prev Rehabil 13 4 (2006) 555-561
19. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., et al. Management of hyperglycemia in type 2 diabetes. A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 8 (2006) 1963-1972
20. Sorkin J.D., Muller D.C., Fleg J.L., and Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 28 11 (2005) 2626-2632
21. Shiraiwa T., Kaneto H., Miyatsuka T., Kato K., Yamamoto K., Kawashima A., et al. Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. Biochem Biophys Res Commun 336 1 (2005) 339-345
22. Levitan E.B., Song Y., Ford E.S., and Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 164 19 (2004) 2147-2155
23. Hanefeld M., Cagatay M., Petrowitsch T., Neuser D., Petzinna D., and Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25 1 (2004) 10-16
24. Woerle H.J., Neumann C., Zschau S., Tenner S., Irsigler A., Schirra J., et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract (2007)
25. Hanefeld M., Koehler C., Schaper F., Fuecker K., Henkel E., and Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 144 1 (1999) 229-235
26. Polonsky K.S., Given B.D., and Van C.E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 81 2 (1988) 442-448
27. American Diabetes Association. Postprandial blood glucose (Consensus Statement). Diabetes Care 24 4 (2001) 775-778
28. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO/IDF Consultation (2006), WHO. http://www.who.int 1-46
29. Weyer C., Bogardus C., Mott D.M., and Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104 6 (1999) 787-794
30. Pratley R.E., and Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 44 8 (2001) 929-945
31. Gerich J.E. Pathogenesis and treatment of type 2 (noninsulin-dependent) diabetes mellitus (NIDDM). Horm Metab Res 28 9 (1996) 404-412
32. Fineman M.S., Koda J.E., Shen L.Z., Strobel S.A., Maggs D.G., Weyer C., et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 51 5 (2002) 636-641
33. Koda J.E., Fineman M., Rink T.J., Dailey G.E., Muchmore D.B., and Linarelli L.G. Amylin concentrations and glucose control. Lancet 339 8802 (1992) 1179-1180
34. Holst J.J., and Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 287 2 (2004) E199-E206
35. Toft-Nielsen M.B., Damholt M.B., Madsbad S., Hilsted L.M., Hughes T.E., Michelsen B.K., et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86 8 (2001) 3717-3723
36. Monnier L., Colette C., Dunseath G.J., and Owens D.R. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30 2 (2007) 263-269
37. Akbar D.H. Sub-optimal postprandial blood glucose level in diabetics attending the outpatient clinic of a University Hospital. Saudi Med J 24 10 (2003) 1109-1112
38. Erlinger T.P., and Brancati F.L. Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diabetes Care 24 10 (2001) 1734-1738
39. Maia F.F., and Araujo L.R. Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients. Diabetes Res Clin Pract (2006)
40. Bonora E., Corrao G., Bagnardi V., Ceriello A., Comaschi M., Montanari P., et al. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 49 5 (2006) 846-854
41. Hanefeld M., Fischer S., Julius U., Schulze J., Schwanebeck U., Schmechel H., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia 39 12 (1996) 1577-1583
42. Brohall G., Oden A., and Fagerberg B. Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabet Med 23 6 (2006) 609-616
43. Coutinho M., Gerstein H.C., Wang Y., and Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22 2 (1999) 233-240
44. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 354 9179 (1999) 617-621
45. DECODE Study Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?. Diabetes Care 26 3 (2003) 688-696
46. Burke G.L., Evans G.W., Riley W.A., Sharrett A.R., Howard G., Barnes R.W., et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 26 3 (1995) 386-391
47. O'Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L., and Wolfson Jr. S.K. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340 1 (1999) 14-22
48. Ceriello A., Falleti E., Motz E., Taboga C., Tonutti L., Ezsol Z., et al. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res 30 3 (1998) 146-149
49. Cominacini L., Fratta P.A., Garbin U., Campagnola M., Davoli A., Rigoni A., et al. E-selectin plasma concentration is influenced by glycaemic control in NIDDM patients: possible role of oxidative stress. Diabetologia 40 5 (1997) 584-589
50. Nappo F., Esposito K., Cioffi M., Giugliano G., Molinari A.M., Paolisso G., et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 39 7 (2002) 1145-1150
51. Esposito K., Nappo F., Marfella R., Giugliano G., Giugliano F., Ciotola M., et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106 16 (2002) 2067-2072
52. Marfella R., Quagliaro L., Nappo F., Ceriello A., and Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 108 4 (2001) 635-636
53. Williams S.B., Goldfine A.B., Timimi F.K., Ting H.H., Roddy M.A., Simonson D.C., et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97 17 (1998) 1695-1701
54. Khatri J.J., Johnson C., Magid R., Lessner S.M., Laude K.M., Dikalov S.I., et al. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation 109 4 (2004) 520-525
55. von Harsdorf R., Li P.F., and Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation 99 22 (1999) 2934-2941
56. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 6865 (2001) 813-820
57. Gerich J.E. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 163 11 (2003) 1306-1316
58. Risso A., Mercuri F., Quagliaro L., Damante G., and Ceriello A. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 281 5 (2001) E924-E930
59. Quagliaro L., Piconi L., Assaloni R., Martinelli L., Motz E., and Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52 11 (2003) 2795-2804
60. Piconi L., Quagliaro L., Da R.R., Assaloni R., Giugliano D., Esposito K., et al. Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADPribose) polymerase. J Thromb Haemost 2 8 (2004) 1453-1459
61. Cavalot F., Petrelli A., Traversa M., Bonomo K., Fiora E., Conti M., et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 91 3 (2006) 813-819
62. Ceriello A., Quagliaro L., Piconi L., Assaloni R., Da R.R., Maier A., et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 53 3 (2004) 701-710
63. Kawano H., Motoyama T., Hirashima O., Hirai N., Miyao Y., Sakamoto T., et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34 1 (1999) 146-154
64. Abbatecola A.M., Rizzo M.R., Barbieri M., Grella R., Arciello A., Laieta M.T., et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 67 2 (2006) 235-240
65. Gapstur S.M., Gann P.H., Lowe W., Liu K., Colangelo L., and Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 283 19 (2000) 2552-2558
66. Larsson S.C., Bergkvist L., and Wolk A. Consumption of sugar and sugar-sweetened foods and the risk of pancreatic cancer in a prospective study. Am J Clin Nutr 84 5 (2006) 1171-1176
67. Michaud D.S., Liu S., Giovannucci E., Willett W.C., Colditz G.A., and Fuchs C.S. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. J Natl Cancer Inst 94 17 (2002) 1293-1300
68. Michaud D.S., Fuchs C.S., Liu S., Willett W.C., Colditz G.A., and Giovannucci E. Dietary glycemic load,carbohydrate, sugar, and colorectal cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 14 1 (2005) 138-147
69. Lajous M., Willett W., Lazcano-Ponce E., Sanchez-Zamorano L.M., and Hernandez-Avila M. Romieu Glycemic load, glycemic index, and the risk of breast cancer among Mexican women. Cancer Causes Control 16 10 (2005) 1165-1169
70. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295 14 (2006) 1681-1687
71. Hasegawa G., Yamamoto Y., Zhi J.G., Tanino Y., Yamasaki M., Yano M., et al. Daily profile of plasma %CoQ10 level, a biomarker of oxidative stress, in patients with diabetes manifesting postprandial hyperglycaemia. Acta Diabetol 42 4 (2005) 179-181
72. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 6423 (1993) 801-809
73. Scognamiglio R., Negut C., De Kreutzenberg S.V., Tiengo A., and Avogaro A. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 112 2 (2005) 179-184
74. Stattin P., Bjor O., Ferrari P., Lukanova A., Lenner P., Lindahl B., et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 30 3 (2007) 561-567
75. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., and Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290 4 (2003) 486-494
76. Esposito K., Giugliano D., Nappo F., and Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110 2 (2004) 214-219
77. Ceriello A., Quagliaro L., Catone B., Pascon R., Piazzola M., Bais B., et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 25 8 (2002) 1439-1443
78. Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 16 2 (2000) 125-132
79. Beisswenger P.J., Howell S.K., O'Dell R.M., Wood M.E., Touchette A.D., and Szwergold B.S. alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 24 4 (2001) 726-732
80. Shimabukuro M., Higa N., Chinen I., Yamakawa K., and Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 91 3 (2006) 837-842
81. Scognamiglio R., Negut C., De Kreutzenberg S.V., Tiengo A., and Avogaro A. Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients. Diabetes Care 29 1 (2006) 95-100
82. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26 3 (2003) 881-885
83. Yki-Jarvinen H., Kauppinen-Makelin R., Tiikkainen M., Vahatalo M., Virtamo H., Nikkila K., et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49 3 (2006) 442-451
84. Riddle M.C., Rosenstock J., and Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 11 (2003) 3080-3086
85. Bastyr III E.J., Stuart C.A., Brodows R.G., Schwartz S., Graf C.J., Zagar A., et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 23 9 (2000) 1236-1241
86. Foster-Powell K., Holt S.H., and Brand-Miller J.C. International table of glycemic index and glycemic load values: 2002. Am J Clin Nutr 76 1 (2002) 5-56
87. McMillan-Price J., Petocz P., Atkinson F., O'neill K., Samman S., Steinbeck K., et al. Comparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults: a randomized controlled trial. Arch Intern Med 166 14 (2006) 1466-1475
88. Wolever T.M., Yang M., Zeng X.Y., Atkinson F., and Brand-Miller J.C. Food glycemic index, as given in glycemic index tables, is a significant determinant of glycemic responses elicited by composite breakfast meals. Am J Clin Nutr 83 6 (2006) 1306-1312
89. Sheard N.F., Clark N.G., Brand-Miller J.C., Franz M.J., Pi-Sunyer F.X., Mayer-Davis E., et al. Dietary carbohydrate (amount and type) in the prevention and management of diabetes: a statement by the American Diabetes Association. Diabetes Care 27 9 (2004) 2266-2271
90. Brand-Miller J.C., Petocz P., and Colagiuri S. Meta-analysis of low-glycemic index diets in the management of diabetes: response to Franz. Diabetes Care 26 12 (2003) 3363-3364
91. Salmeron J., Manson J.E., Stampfer M.J., Colditz G.A., Wing A.L., and Willett W.C. Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA 277 6 (1997) 472-477
92. Salmeron J., Ascherio A., Rimm E.B., Colditz G.A., Spiegelman D., Jenkins D.J., et al. Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care 20 4 (1997) 545-550
93. Zhang C., Liu S., Solomon C.G., and Hu F.B. Dietary fiber intake, dietary glycemic load, and the risk for gestational diabetes mellitus. Diabetes Care 29 10 (2006) 2223-2230
94. Liu S., Willett W.C., Stampfer M.J., Hu F.B., Franz M., Sampson L., et al. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr 71 6 (2000) 1455-1461
95. Opperman A.M., Venter C.S., Oosthuizen W., Thompson R.L., and Vorster H.H. Meta-analysis of the health effects of using the glycaemic index in mealplanning. Br J Nutr 92 3 (2004) 367-381
96. Ahren B., and Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 36 11-12 (2004) 867-876
97. Briones M., and Bajaj M. Exenatide: a GLP-1 receptor agonist as novel therapy for type 2 diabetes mellitus. Expert Opin Pharmacother 7 8 (2006) 1055-1064
98. Ceriello A., Piconi L., Quagliaro L., Wang Y., Schnabel C.A., Ruggles J.A., et al. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 28 3 (2005) 632-637
99. Weyer C., Maggs D.G., Young A.A., and Kolterman O.G. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 7 14 (2001) 1353-1373
100. Goke B., and Herrmann-Rinke C. The evolving role of alpha-glucosidase inhibitors. Diabetes Metab Rev 14 Suppl. 1 (1998) S31-S38
101. Lebovitz H.E. alpha-Glucosidase inhibitors. Endocrinol Metab Clin North Am 26 3 (1997) 539-551
102. Samsom M., Szarka L.A., Camilleri M., Vella A., Zinsmeister A.R., and Rizza R.A. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol Gastrointest Liver Physiol 278 6 (2000) G946-G951
103. Fineman M., Weyer C., Maggs D.G., Strobel S., and Kolterman O.G. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 34 9 (2002) 504-508
104. Thompson R.G., Peterson J., Gottlieb A., and Mullane J. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes 46 4 (1997) 632-636
105. Thompson R.G., Gottlieb A., Organ K., Koda J., Kisicki J., and Kolterman O.G. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabet Med 14 7 (1997) 547-555
106. Whitehouse F., Kruger D.F., Fineman M., Shen L., Ruggles J.A., Maggs D.G., et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25 4 (2002) 724-730
107. Kruger D.F., and Gloster M.A. Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data. Drugs 64 13 (2004) 1419-1432
108. Maggs D.G., Fineman M., Kornstein J., Burrell T., Schwartz S., Wang Y., et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev 20 1 (2004) 55-60
109. Wolffenbuttel B.H., Nijst L., Sels J.P., Menheere P.P., Muller P.G., and Kruseman A.C. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur J Clin Pharmacol 45 2 (1993) 113-116
110. Hirschberg Y., Karara A.H., Pietri A.O., and McLeod J.F. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care 23 3 (2000) 349-353
111. Nattrass M., and Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?. Int J Obes Relat Metab Disord 24 Suppl. 3 (2000) S21-S31
112. Flint A., Raben A., Ersboll A.K., Holst J.J., and Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25 6 (2001) 781-792
113. Ritzel R., Orskov C., Holst J.J., and Nauck M.A. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia 38 6 (1995) 720-725
114. Schirra J., Houck P., Wank U., Arnold R., Goke B., and Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 46 5 (2000) 622-631
115. Drucker D.J. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 144 12 (2003) 5145-5148
116. Abraham E.J., Leech C.A., Lin J.C., Zulewski H., and Habener J.F. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 143 8 (2002) 3152-3161
117. DeWitt D.E., and Hirsch I.B. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 289 17 (2003) 2254-2264
118. Halimi S., Raskin P., Liebl A., Kawamori R., Fulcher G., and Yan G. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clin Ther 27 Suppl. 2 (2005) S57-S74
119. Kazda C., Hulstrunk H., Helsberg K., Langer F., Forst T., and Hanefeld M. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complicat 20 3 (2006) 145-152
120. Schernthaner G., Kopp H.P., Ristic S., Muzyka B., Peter L., and Mitteregger G. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70. Horm Metab Res 36 3 (2004) 188-193
121. Roach P., and Malone J.K. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes. Diabet Med 23 7 (2006) 743-749
122. Royle P., Waugh N., McAuley L., McIntyre L., and Thomas S. Inhaled insulin in diabetes mellitus. Cochrane Database Syst Rev 3 (2004) CD003890
123. American Diabetes Association. Clinical Practice Recommendations 2007: diagnosis and classification of diabetes mellitus. Diabetes Care 30 Suppl. 1 (2007) S42-S47
124. American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus. Endocr Pract 8 (2003) 40-65
125. El-Kebbi I.M., Ziemer D.C., Cook C.B., Gallina D.L., Barnes C.S., and Phillips L.S. Utility of casual postprandial glucose levels in type 2 diabetes management. Diabetes Care 27 2 (2004) 335-339
126. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13 Suppl. 1 (2007) 5-68
127. Global guideline for type 2 diabetes. IDF Task Force on Clinical Guidelines (2006), International Diabetes Federation. http://www.idf.org
128. American Diabetes Association. Clinical practice recommendations 2007: standards of medical care in diabetes - 2007. Diabetes Care 30 Suppl. 1 (2007) S4-S41
129. Murata G.H., Shah J.H., Hoffman R.M., Wendel C.S., Adam K.D., Solvas P.A., et al. Intensified blood glucose monitoring improves glycemic control in stable, insulin-treated veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Diabetes Care 26 6 (2003) 1759-1763
130. Martin S., Schneider B., Heinemann L., Lodwig V., Kurth H.J., Kolb H., et al. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 49 2 (2006) 271-278
131. Schwedes U., Siebolds M., and Mertes G. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. Diabetes Care 25 11 (2002) 1928-1932
132. Moreland E.C., Volkening L.K., Lawlor M.T., Chalmers K.A., Anderson B.J., and Laffel L.M. Use of a blood glucose monitoring manual to enhance monitoring adherence in adults with diabetes: a randomized controlled trial. Arch Intern Med 166 6 (2006) 689-695
133. Jansen J.P. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin 22 4 (2006) 671-681
134. Sarol Jr. J.N., Nicodemus Jr. N.A., Tan K.M., and Grava M.B. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966-2004). Curr Med Res Opin 21 2 (2005) 173-184
135. Coster S., Gulliford M.C., Seed P.T., Powrie J.K., and Swaminathan R. Self-monitoring in type 2 diabetes mellitus: a meta-analysis. Diabet Med 17 11 (2000) 755-761
136. Allen B.T., DeLong E.R., and Feussner J.R. Impact of glucose self-monitoring on non-insulin-treated patients with type II diabetes mellitus. Randomized controlled trial comparing blood and urine testing. Diabetes Care 13 10 (1990) 1044-1050
137. Farmer A., Wade A., Goyder E., Yudkin P., French D., Craven A., et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 335 7611 (2007) 132
138. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 27 (2003) S21
139. Chase H.P., Kim L.M., Owen S.L., MacKenzie T.A., Klingensmith G.J., Murtfeldt R., et al. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics 107 2 (2001) 222-226
140. Garg S., Zisser H., Schwartz S., Bailey T., Kaplan R., Ellis S., et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 29 1 (2006) 44-50
141. Bode B.W., Gross T.M., Thornton K.R., and Mastrototaro J.J. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract 46 3 (1999) 183-190
142. Guerci B., Floriot M., Bohme P., Durain D., Benichou M., Jellimann S., et al. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs. Diabetes Care 26 3 (2003) 582-589
143. Yamanouchi T., Moromizato H., Shinohara T., Minoda S., Miyashita H., and Akaoka I. Estimation of plasma glucose fluctuation with a combination test of hemoglobin A1c and 1,5-anhydroglucitol. Metabolism 41 8 (1992) 862-867
144. Yamanouchi T., Ogata N., Tagaya T., Kawasaki T., Sekino N., Funato H., et al. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet 347 9014 (1996) 1514-1518
145. Fukumura Y., Tajima S., Oshitani S., Ushijima Y., Kobayashi I., Hara F., et al. Fully enzymatic method for determining 1,5-anhydro-d-glucitol in serum. Clin Chem 40 11 Pt 1 (1994) 2013-2016
146. McGill J.B., Cole T.G., Nowatzke W., Houghton S., Ammirati E.B., Gautille T., et al. Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care 27 8 (2004) 1859-1865